Is ABBV stock a Buy, Sell, or Hold?

Based on our analysis, ABBV is currently a WAIT with low confidence. 📊 MIXED SIGNALS: ABBV shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of ABBV stock?

Our analysis estimates the fair value range for ABBV to be between $246.40 and $259.65. The current price is $264.96.

What is the analyst price target for ABBV?

The average Wall Street analyst price target for ABBV is $276.59. This implies a potential upside of 4.4% from current levels.

ABBV Stock Analysis: Buy, Sell, or Hold?

ABBV - ABBVIE INC.

PHARMACEUTICAL PREPARATIONS

$264.96

3.13 (1.20%) ▲

5d: +6.21%

30d: +3.13%

90d: +23.52%

WAIT

LOW Confidence

Protect Your ABBV Gains

Analysis Updated: Aug 21, 2026 12:00 AM ET

Earnings: Jul 31, 2026 0d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Aug 7, 2026 at $246.04 · last confirmed Aug 17, 2026

Strength: 8.0/10

Get Alerted When ABBV Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: ABBV shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 16.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$375.35

Based on 10.0% avg growth

INTRINSIC VALUE TODAY

$233.06

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.4x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: ABBV is currently trading at $264.96, which is considered extended relative to its 30-day fair value range of $246.40 to $259.65. From a valuation perspective, the stock is trading at a premium (Forward PE: 16.3) compared to its historical average (14.4). At these levels, the market is pricing in 4.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, ABBV is in a strong uptrend. The price is approaching resistance at $266.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: ABBV scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED

Historical Trading Range $246.40 - $259.65

Company Quality Score 41/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 24.8%

Protect Your Profits

Holding ABBV? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BEARISH: Price extended above range
BEARISH: Weak technical setup (25/100)
BULLISH: High volume confirmation
NEUTRAL: Near Wall St target ($276.59)
NEUTRAL: Market pricing in 4.1% annual earnings growth - fairly valued
WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $246.40 - $259.65

Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $244.03

Resistance Level $266.97

Current Trend Strong Uptrend

Technical data as of Aug 21, 2026

Fundamental Context

Forward P/E (Next Year Est.) 16.31

Wall Street Target $276.59 (+4.4%)

Revenue Growth (YoY) 10.2%

Earnings Growth (YoY) 290.4%

Profit Margin 9.8%

Valuation Premium vs History +4.1% premium

PE vs Historical 16.3 vs 14.4 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +4.1% (market-implied from PE analysis)

1-Year Target $275.82 (+4%)

2-Year Target $287.13 (+8%)

3-Year Target $298.90 (+13%)

3-Yr Target (if PE normalizes) (PE: 16→14) PE COMPRESSION $263.90 (0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.1, Growth: 16.0%) $508.37 (+92%)

Base: (SPY PE: 16.3, Growth: 16.0%) $413.13 (+56%)

Bear: (PE: 13.9, Growth: 16.0%) $351.16 (+33%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (16x PE) as earnings recover.

Forward PE: 18.94 | Forward EPS (Implied): $13.99

Bull Case $319.94 (+21%)

Analyst growth 15.0%, PE expands to 19.9

Base Case $264.96 (0%)

Market implied 0.0%, PE stable at 18.9

Bear Case $202.69 (-24%)

Severe decline -15.0%, PE contracts to 17.1

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: August 23, 2026 1:36 AM ET
Data refreshes hourly during market hours. Next update: 2:36 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is ABBV showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Ro Khanna SELL 2026-03-30

David Ryan Purdue SELL 5230 shares 2026-03-04

Perry C Siatis SELL 22381 shares 2026-02-25

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for ABBV.

Create Free Account

Already have an account? Log In

Featured in Portfolios

ABBV is a key holding in these high-performance investment strategies.

Healthcare Giants Sector • +21.5% Return

View All Strategies

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1311	37 SELL
GILD Gilead Sciences Inc	BUY 30 analysts	$157	34 SELL
BIIB Biogen Inc	HOLD 37 analysts	$238	42 HOLD
AMGN Amgen Inc	HOLD 32 analysts	$384	38 SELL
MRK Merck & Company Inc	BUY 26 analysts	$138	45 HOLD

LLY Eli Lilly and Com…

37 SELL

GILD Gilead Sciences I…

MRK Merck & Company I…

45 HOLD

Advanced ABBV Option Strategies

Professional options setups generated by AI based on today's ABBV price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ABBV

ABBV Technical Chart ABBV Price Prediction ABBV Earnings Date ABBV Investment Advisor ABBV Fair Price Analyzer ABBV Options Advisor ABBV Options Chain ABBV Options Analysis ABBV Competitors

Compare ABBV with Peers

ABBV vs ABT
Which one to buy?

ABBV vs BMY
Which one to buy?

ABBV vs JNJ
Which one to buy?

ABBV vs GILD
Which one to buy?

ABBV vs MRK
Which one to buy?

VERU vs ABBV

GALT vs ABBV

OLMA vs ABBV
Winner: ABBV

Create New Comparison View All Competitors

Tradestie